The key takeaways for this program are:
- Understanding the Prometheus decision and what the Supreme Court did and did not say;
- Understanding the question at issue in Myriad and how it is similar—and different—from that decided in Prometheus;
- Learning possible patent claim strategies to protect personalized medicine methods and biotechnology inventions under the new paradigm;
- Reviewing the U.S. Patent Office Guidance to Examiners, issued shortly after the Supreme Court decided Prometheus; and
- Discussing Options for strengthening already granted patents.
People
Related Insights
December 24, 2025
Health Care Law Today
Gender-Affirming Care: Multi‑State Lawsuit Challenges HHS Declaration
As previously discussed in Foley’s healthcarelawtoday, on December 18, 2025, the U.S. Department of Health & Human Services (HHS) held a press conference focused on what it defined as “sex rejection procedures” (SRPs), also known as gender-affirming care (GAC) for minors, and outlined next steps.
December 23, 2025
Energy Current
FERC Opens New Paths for Co-Located Loads in PJM: What Data Center and Power Generation Developers Need to Know
Key Takeaways FERC has ordered PJM to overhaul its tariff framework for co-located generation and large loads, finding existing rules…
December 23, 2025
Foley Viewpoints
The Rush to Exit: PE Firms Pick Up the Pace in 2025
Key Points: PE firms are moving to sell portfolio companies on an accelerated timeline in 2025 after years of much longer hold…